www.nejm.org/doi/full/10....
Very exciting to hear about this ground breaking clinical trial at #era2025
nejm.org
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | NEJM
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chr...